AbCellera Biologics Inc. Payments to Acquire Equity Method Investments
AbCellera Biologics Inc. (ABCL) reported Payments to Acquire Equity Method Investments of $7.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2026-02-24
- AbCellera Biologics Inc. payments to acquire equity method investments for the quarter ending 2025-12-31 was $251.00K, a 84.97% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire equity method investments for the quarter ending 2025-09-30 was $2.45M, a 65.65% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire equity method investments for the quarter ending 2025-06-30 was $2.55M, a 48.06% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire equity method investments for the quarter ending 2025-03-31 was $1.88M, a 68.12% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire equity method investments for fiscal 2025 was $7.14M, a 63.63% decline from fiscal 2024.
- AbCellera Biologics Inc. payments to acquire equity method investments for fiscal 2024 was $19.63M, a 43.36% increase from fiscal 2023.
- AbCellera Biologics Inc. payments to acquire equity method investments for fiscal 2023 was $13.69M, a 46.69% decline from fiscal 2022.
- AbCellera Biologics Inc. payments to acquire equity method investments for fiscal 2022 was $25.68M, a 15.32% decline from fiscal 2021.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.70M derived: sum of 2 quarters · filed 2026-02-24 | $5.25M derived: sum of 3 quarters · filed 2026-02-24 | $7.14M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.00M derived: sum of 2 quarters · filed 2025-11-06 | $6.89M 10-Q · filed 2025-11-06 | $8.56M derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | $2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.43M 10-Q · filed 2025-08-07 | $6.11M derived: sum of 3 quarters · filed 2026-02-24 | $13.24M derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | $1.88M 10-Q · filed 2025-05-08 | $3.55M derived: sum of 2 quarters · filed 2026-02-24 | $10.69M derived: sum of 3 quarters · filed 2026-02-24 | $15.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.81M derived: sum of 2 quarters · filed 2026-02-24 | $13.72M derived: sum of 3 quarters · filed 2026-02-24 | $19.63M 10-K · filed 2026-02-24 |
| 2024-09-30 | $7.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $12.05M derived: sum of 2 quarters · filed 2025-11-06 | $17.96M 10-Q · filed 2025-11-06 | $21.43M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $4.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $10.82M 10-Q · filed 2025-08-07 | $14.30M derived: sum of 3 quarters · filed 2026-02-24 | $17.84M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $5.91M 10-Q · filed 2025-05-08 | $9.38M derived: sum of 2 quarters · filed 2026-02-24 | $12.92M derived: sum of 3 quarters · filed 2026-02-24 | $15.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.02M derived: sum of 2 quarters · filed 2026-02-24 | $9.22M derived: sum of 3 quarters · filed 2026-02-24 | $13.69M 10-K · filed 2026-02-24 |
| 2023-09-30 | $3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $5.75M derived: sum of 2 quarters · filed 2024-11-04 | $10.21M 10-Q · filed 2024-11-04 | $16.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.67M 10-Q · filed 2024-08-06 | $12.58M derived: sum of 3 quarters · filed 2025-02-27 | $16.66M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.47M 10-Q · filed 2024-05-07 | $10.38M derived: sum of 2 quarters · filed 2025-02-27 | $14.45M derived: sum of 3 quarters · filed 2025-02-27 | $21.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $9.98M derived: sum of 2 quarters · filed 2025-02-27 | $17.34M derived: sum of 3 quarters · filed 2025-02-27 | $25.68M 10-K · filed 2025-02-27 |
| 2022-09-30 | $4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $11.44M derived: sum of 2 quarters · filed 2023-11-02 | $19.77M 10-Q · filed 2023-11-02 | $22.99M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $7.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $15.69M 10-Q · filed 2023-08-03 | $18.91M derived: sum of 3 quarters · filed 2024-02-20 | $25.51M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $8.34M 10-Q · filed 2023-05-04 | $11.55M derived: sum of 2 quarters · filed 2024-02-20 | $18.15M derived: sum of 3 quarters · filed 2024-02-20 | $26.46M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $9.81M derived: sum of 2 quarters · filed 2024-02-20 | $18.13M derived: sum of 3 quarters · filed 2024-02-20 | $30.32M 10-K · filed 2024-02-20 |
| 2021-09-30 | $6.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $14.91M derived: sum of 2 quarters · filed 2022-11-08 | $27.11M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $8.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $20.51M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $12.20M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $19.25M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |